Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human pharmacokinetics of marcellomycin.

P Dodion, M Rozencweig, C Nicaise

    Cancer Chemotherapy and Pharmacology
    |January 1, 1985
    PubMed
    Summary

    This study examined marcellomycin (MCM) pharmacokinetics in cancer patients. MCM showed predictable drug clearance, with metabolites persisting longer than the parent drug.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [National protocol for diagnosis and care of retinopathy of prematurity: Summary for the attending physician].

    Journal francais d'ophtalmologie·2024
    Same author

    Lipoteichoic acid stimulates the proliferation, migration and cytokine production of adult dental pulp stem cells without affecting osteogenic differentiation.

    International endodontic journal·2020
    Same author

    Is the T-ligament a ligament? A histological study in equine cadaver forelimbs.

    Research in veterinary science·2020
    Same author

    Thoracic ultrasound accuracy for the investigation of initial neonatal respiratory distress.

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2019
    Same author

    Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2019
    Same author

    Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2014

    Area of Science:

    • Pharmacology
    • Oncology
    • Drug Metabolism

    Background:

    • Marcellomycin (MCM) is a novel class II anthracycline antibiotic.
    • Understanding MCM's pharmacokinetic profile is crucial for its clinical application.

    Purpose of the Study:

    • To investigate the pharmacokinetics of marcellomycin (MCM) in cancer patients.
    • To characterize the absorption, distribution, metabolism, and excretion of MCM.

    Main Methods:

    • Phase I clinical trials involving nine patients with normal organ function.
    • Intravenous infusion of MCM at 27.5, 40, or 50 mg/m2.
    • Plasma and urine sample analysis using thin-layer chromatography and fluorescence quantification up to 72 hours.

    Main Results:

    • Plasma MCM concentrations followed first-order kinetics, disappearing by 48 hours.
    • Metabolites (M2, P1, P2, G1, G2) were identified, with some having higher AUCs due to persistence.
    • Urinary excretion of total fluorescence was approximately 7-8% of the administered dose.

    Conclusions:

    • MCM exhibits predictable pharmacokinetics with triexponential disappearance from plasma.
    • Metabolite profiles suggest longer systemic exposure to breakdown products than to MCM itself.
    • No correlation was found between pharmacokinetic parameters and observed toxicities.

    Related Experiment Videos